Paroxetine Dosing for Panic Disorder
For panic disorder in adults, start paroxetine at 10 mg daily and titrate to a target dose of 40 mg daily, as this is the minimum dose demonstrated to be significantly superior to placebo. 1, 2
Initial Dosing Strategy
- Starting dose: 10 mg daily
- Target therapeutic dose: 40 mg daily
- Titration schedule: Increase in 10 mg increments weekly as tolerated
- Dose range: 10-60 mg daily (though doses above 40 mg show minimal additional benefit)
The FDA label clearly establishes that 40 mg/day is the minimum effective dose, with 76% of patients at this dose becoming panic-free compared to 44% on placebo 1. While some patients respond at 10-20 mg daily (65-67% panic-free), only the 40 mg dose achieved statistical superiority across the majority of outcome measures 2.
Titration Considerations
Start with a subtherapeutic "test" dose to minimize initial anxiety or agitation, which are common early adverse effects of SSRIs 3. Given paroxetine's shorter half-life, dose increases should occur at 1-2 week intervals rather than the 3-4 weeks needed for longer half-life SSRIs like fluoxetine 3.
A 2010 study 4 found minimal benefit to ultra-slow titration (2.5 mg increments every 2 days) versus standard weekly 10 mg increases, showing only slight superiority in the first 9 days. Therefore, standard weekly titration is appropriate for most patients.
Dosing Range and Optimization
- Flexible dosing studies used 10-60 mg daily, with mean endpoint doses around 40 mg/day 1
- Maximum dose: 60 mg daily, though evidence suggests no additional benefit beyond 40 mg for most patients
- Controlled-release formulation: 25-75 mg daily showed 63% panic-free rate versus 53% with placebo 5
Critical Safety Warnings
Paroxetine has specific risks that warrant caution:
- Discontinuation syndrome risk: Paroxetine is notably associated with withdrawal symptoms (dizziness, paresthesias, anxiety, nausea) upon missed doses or abrupt discontinuation 3
- Increased suicidal thinking: Paroxetine carries higher risk compared to other SSRIs, particularly in adolescents and young adults 3, 6
- Drug interactions: Metabolized by CYP2D6; avoid MAOIs and use caution with other serotonergic drugs 3
Comparative Efficacy
A 2007 head-to-head trial 7 showed venlafaxine ER 225 mg had slightly superior outcomes to paroxetine 40 mg (70% vs 58.3% panic-free), though both were effective. A 2004 comparison 8 found sertraline and paroxetine equally effective, but sertraline was better tolerated with less weight gain and less clinical worsening during taper.
Maintenance Treatment
Long-term data support continued efficacy: Patients who responded to paroxetine during acute treatment (10-40 mg/day) and continued for 3 months were significantly less likely to relapse than those switched to placebo 1. This supports continuation at the effective dose for relapse prevention.
Practical Algorithm
- Week 1: Start 10 mg daily (consider as "test dose")
- Week 2: Increase to 20 mg daily if tolerated
- Week 3: Increase to 30 mg daily
- Week 4: Increase to 40 mg daily (target dose)
- Weeks 4-10: Maintain 40 mg; assess response by week 4-6
- If inadequate response at week 6-8: Consider increase to 50-60 mg daily, though evidence for additional benefit is limited
Monitor closely for: Treatment-emergent anxiety (first 2-4 weeks), suicidal ideation (especially first 24-48 hours after dose changes), and adherence 3.